Page last updated: 2024-09-05

sorafenib and Adrenocortical Carcinoma

sorafenib has been researched along with Adrenocortical Carcinoma in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Amendola, D; Bucci, B; Cerquetti, L; Lardo, P; Maggio, R; Petrangeli, E; Pugliese, G; Raffa, S; Stigliano, A; Torrisi, MR; Toscano, V	1
Chow, ML; Compoginis, G; Crew, AB; Ochoa, MT; Salame, N	1
Ardito, A; Baudin, E; Berruti, A; Daffara, F; De Francia, S; Ferrero, A; Generali, D; Germano, A; Leboulleux, S; Papotti, M; Perotti, P; Priola, AM; Sperone, P; Terzolo, M; Volante, M	1

Trials

1 trial(s) available for sorafenib and Adrenocortical Carcinoma

Article	Year
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. European journal of endocrinology, 2012, Volume: 166, Issue:3 Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib	2012

Article

Year

Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.

European journal of endocrinology, 2012, Volume: 166, Issue:3

Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib

2012

Other Studies

2 other study(ies) available for sorafenib and Adrenocortical Carcinoma

Article	Year
Effects of Sorafenib, a Tyrosin Kinase Inhibitor, on Adrenocortical Cancer. Frontiers in endocrinology, 2021, Volume: 12 Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Sorafenib; Tumor Cells, Cultured	2021
Sorafenib Toxicity Mimicking Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Journal of drugs in dermatology : JDD, 2019, May-01, Volume: 18, Issue:5 Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Diagnosis, Differential; Drug Hypersensitivity Syndrome; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Metastasis; Sorafenib	2019

Article

Year

Effects of Sorafenib, a Tyrosin Kinase Inhibitor, on Adrenocortical Cancer.

Frontiers in endocrinology, 2021, Volume: 12

Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Sorafenib; Tumor Cells, Cultured

2021

Sorafenib Toxicity Mimicking Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Syndrome

Journal of drugs in dermatology : JDD, 2019, May-01, Volume: 18, Issue:5

Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Antineoplastic Agents; Diagnosis, Differential; Drug Hypersensitivity Syndrome; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Middle Aged; Neoplasm Metastasis; Sorafenib

2019